glp-1 receptor agonist pancreatitis risk meta-analysis Frontiers GLP-1 RAs and Pancreatitis: No

Safety Backed by Research The safety of GLP-1 medications is well-supported by extensive research

In-person visits are still important when vitals, labs, exam, or safety issues need hands-on assessment No

The agency's decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for the treatment

In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]

Improved blood sugar control (slower glucose spikes)

40 Preclinical studies have shown that these effects are mainly mediated trough the effects of GLP-1R activation in the central nervous system (CNS) by the modulation of orexigenic and anorexigenic signaling pathways